We have optimized peripheral blood assays for measuring IL-17 responses, but as part of an ongoing study in a new group of CRC patients, peripheral blood–derived CEA-specific IL-17–producing T-cells are observed in less than 5% of patients (data not shown). Here, IL17A is linked to colorectal carcinoma.